Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CELLTOP: Autologous AD-MSCs for Traumatic Spinal Cord Injury
NCT03308565Phase 1Completed
- Start
- Dec 2017
- Primary completion
- Oct 2019
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous adipose-derived mesenchymal stromal cells in spinal cord injury (SCI). Primary endpoint: Incidence of acute adverse events at 4 weeks. Started Dec 2017; status: completed.
02
Drugs
autologous adipose-derived mesenchymal stromal cells
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT03308565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03308565.